EVE Health has signed a binding agreement giving it a 75% share of distributable profit from compounded men’s sexual health products in Australia. The capital-light arrangement preserves EVE’s intellectual property ownership, but provides no minimum volumes or guaranteed revenue.
- Binding compounding agreement with Optimal Pharmacy Plus Stafford
- EVE to receive 75% of profit available for distribution
- Pharmacy partner handles sourcing, compounding, dispensing and delivery
- First supply depends on technology transfer and validation
- No minimum volumes or guaranteed revenue
EVE secures pharmacy route for men’s health formulations
EVE Health Group Limited (ASX:EVE) has created a potential Australian revenue channel for its proprietary men’s sexual health technology without building a compounding operation of its own. The company has signed a binding Master Compounding and Profit Share Agreement with Optimal Pharmacy Plus Stafford, which will compound, dispense and deliver the products while EVE supplies the formulation technology and technical support.
The commercial attraction is the split: EVE is entitled to 75% of profit available for distribution after direct compounding and delivery costs, with Optimal receiving the remaining 25%. That profit measure excludes GST, refunds and chargebacks, and deducts ingredients, packaging, delivery and a fixed per-unit labour rate. EVE will also meet telehealth partner support fees from its own 75% share.
Capital-light model keeps EVE’s intellectual property intact
The arrangement gives EVE a partner-led route into a men’s sexual health market that the company describes as large and increasingly accessed through telehealth. Its range is based on patent-pending nano-emulsion technology intended to address erectile dysfunction and premature ejaculation, conditions EVE says commonly occur together.
The model extends the partner-led commercialisation strategy previously outlined in EVE’s capital-light partner model, where two products were launched through Australia’s SAS-B pathway. Under the new agreement, EVE retains ownership of the formulation and all related intellectual property, including improvements made under the contract. It also keeps open the option of pursuing a registered product in the future.
First supply remains the key commercial test
Products will not reach patients immediately. First supply depends on completing technology transfer, validation and other conditions, after which EVE plans to engage telehealth partners. Prescribing decisions will remain with independent clinicians, and each product will be compounded for an individual patient against a valid prescription.
The agreement offers no minimum volumes or guaranteed revenue, and EVE said it cannot yet estimate how much income it may generate. The eventual outcome will depend on the timing of first supply, clinician prescribing, patient demand, pricing and costs. Optimal has an exclusive Australian appointment for the initial products from first supply and must not compound or supply competing formulations.
Compounding status separates the range from Libbo
EVE stressed that the agreement is separate from its Libbo vardenafil oral soluble film program, which continues along its bioequivalence and registration pathway. Unlike registered medicines, compounded products are not included on the Australian Register of Therapeutic Goods and have not been assessed by the Therapeutic Goods Administration for safety, quality or efficacy.
The initial term runs for two years from first supply and then renews annually unless terminated under the agreement. The immediate milestones are therefore operational rather than financial: completion of validation, commencement of supply and formation of telehealth distribution arrangements. Until those steps occur, the 75% profit share is a contractual possibility rather than an established revenue stream.
Bottom Line?
The agreement gives EVE a low-capital commercial route, but first supply and patient uptake must arrive before the profit split becomes meaningful.
Questions in the middle?
- How quickly will technology transfer and validation allow first supply to begin?
- Will independent clinicians and telehealth partners generate enough prescribing demand to produce material revenue?
- Can EVE expand the model to additional compounded products without creating new regulatory or execution constraints?